Benutzer: Gast  Login
Titel:

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.

Dokumenttyp:
Journal Article
Autor(en):
Stroh, Jacob; Seckinger, Anja; Heider, Michael; Rudelius, Martina; Eichner, Ruth; Schick, Markus; Slawska, Jolanta; Emde-Rajaratnam, Martina; Salwender, Hans; Bertsch, Uta; Goldschmidt, Hartmut; Weisel, Katja; Scheid, Christof; Keller, Ulrich; Hose, Dirk; Bassermann, Florian
Abstract:
Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive. We have shown that immunomodulatory drugs (IMiDs) exert anti-MM activity via destabilization of MCT1 and CD147. In this study, cell samples of 654 patients with MM who received lenalidomide (n = 455), thalidomide (n = 98), or bortezomib (n = 101) maintenance were assessed by gene expression profiling and RNA sequencing, followed by correlation of MCT1 and CD147 expre...     »
Zeitschriftentitel:
Blood Adv
Jahr:
2022
Band / Volume:
6
Heft / Issue:
2
Seitenangaben Beitrag:
515-520
Volltext / DOI:
doi:10.1182/bloodadvances.2021005532
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/34768284
Print-ISSN:
2473-9529
TUM Einrichtung:
1036; Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie
 BibTeX